Promoter methylation analysis of O6-methylguanine-DNA methyltransferase in glioblastoma: Detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Morandi, Luca ^a   Franceschi, Enrico ^b   de Biase, Dario ^a   Marucci, Gianluca ^a   Tosoni, Alicia ^b   Ermani, Mario ^c   Pession, Annalisa ^a   Tallini, Giovanni ^a   Brandes, Alba ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BELLARIA HOSPITAL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 O METHYLGUANINE; BISULFITE; DNA METHYLTRANSFERASE; GENE PRODUCT; LOCKED NUCLEIC ACID; PROTEIN SNURF; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; CARMUSTINE; DACARBAZINE; DRUG DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER SURVIVAL; CHROMOSOME 15Q; CONTROLLED STUDY; CPG ISLAND; DNA ISOLATION; FEMALE; GENE MAPPING; GENETIC DATABASE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN METHYLATION; SENSITIVITY ANALYSIS; BRAIN TUMOR; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; GENOME IMPRINTING; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; DACARBAZINE; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENOMIC IMPRINTING; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 77949460376     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-48     Document Type: Article

References (56)

1. Laird PW. Cancer epigenetics. Hum Mol Genet 2005, 14(Spec No 1):R65-76. 10.1093/hmg/ddi113, 15809275.
2. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054. 10.1056/NEJMra023075, 14627790.
3. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol 2003, 13(2):176-184.
4. Qian XC, Brent TP. Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res 1997, 57(17):3672-3677.
5. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 1997, 17(9):5612-5619. 232409, 9271436.
6. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999, 59(4):793-797.
7. Stupp R, Mason WP, Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996. 10.1056/NEJMoa043330, 15758009.
8. Liu L, Markowitz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res 1996, 56(23):5375-5379.
9. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004, 4(4):296-307. 10.1038/nrc1319, 15057289.
10. Hotta T, Saito Y, Fujita H, Mikami T, Kurisu K, Kiya K, Uozumi T, Isowa G, Ishizaki K, Ikenaga M. O6-alkylguanine-DNA alkyltransferase activity of human malignant glioma and its clinical implications. J Neurooncol 1994, 21(2):135-140. 10.1007/BF01052897, 7861189.
11. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996, 56(4):783-788.
12. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998, 16(10):3310-3315.
13. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998, 16(12):3851-3857.
14. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352(10):997-1003. 10.1056/NEJMoa043331, 15758010.
15. Kress C, Thomassin H, Grange T. Local DNA demethylation in vertebrates: how could it be performed and targeted?. FEBS Lett 2001, 494(3):135-140. 10.1016/S0014-5793(01)02328-6, 11311228.
16. Liu ZJ, Maekawa M. Polymerase chain reaction-based methods of DNA methylation analysis. Anal Biochem 2003, 317(2):259-265. 10.1016/S0003-2697(03)00169-6, 12758266.
17. Cottrell SE, Distler J, Goodman NS, Mooney SH, Kluth A, Olek A, Schwope I, Tetzner R, Ziebarth H, Berlin K. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic Acids Res 2004, 32(1):e10. 10.1093/nar/gnh008, 373310, 14722226.
18. Uhlmann K, Brinckmann A, Toliat MR, Ritter H, Nurnberg P. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 2002, 23(24):4072-4079. 10.1002/elps.200290023, 12481262.
19. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343(19):1350-1354. Erratum, N Engl J Med 2000;1343: 1740, 10.1056/NEJM200011093431901, 11070098.
20. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger SH, Wesseling P. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 2007, 87(10):1055-1065. 10.1038/labinvest.3700664, 17700563.
21. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ. A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 2007, 87(4):392-397.
22. Thomassin H, Oakeley EJ, Grange T. Identification of 5-methylcytosine in complex genomes. Methods 1999, 19(3):465-475. 10.1006/meth.1999.0883, 10579942.
23. Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 2002, 33(3):636-649.
24. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000, 28(8):E32. 10.1093/nar/28.8.e32, 102836, 10734209.
25. Lorente A, Mueller W, Undargarin E, Lázcoz P, vonDeimling A, Castresana JS. Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. BMC Cancer 2008, 8:61. 10.1186/1471-2407-8-61, 2266933, 18298842.
26. Smith E, Jones ME, Drew PA. Quantitation of DNA methylation by melt curve analysis. BMC Cancer 2009, 9:123. 10.1186/1471-2407-9-123, 2679043, 19393074.
27. Vlassenbroeck I, Califice S, Diserens AC, Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M, et al. Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008, 10(4):332-337. 10.2353/jmoldx.2008.070169, 2438202, 18556773.
28. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007, 35(6):e41. 10.1093/nar/gkm013, 1874596, 17289753.
29. Gustafson KS. Locked nucleic acids can enhance the analytical performance of quantitative methylation-specific polymerase chain reaction. J Mol Diagn 2008, 10(1):33-42. 10.2353/jmoldx.2008.070076, 2175541, 18165272.
30. El-Maarri O, Buiting K, Peery EG, Kroisel PM, Balaban B, Wagner K, Urman B, Heyd J, Lich C, Brannan CI, et al. Maternal methylation imprints on human chromosome 15 are established during or after fertilization. Nat Genet 2001, 27(3):341-344. 10.1038/85927, 11242121.
31. Ginzinger DG, Godfrey TE, Nigro J, Moore DH, Suzuki S, Pallavicini MG, Gray JW, Jensen RH. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res 2000, 60(19):5405-5409.
32. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. World Health Organization Classification of Tumours of the Central Nervous System. 2007, IARC Lyon.
33. Morandi L, Marucci G, Foschini MP, Cattani MG, Pession A, Riva C, Eusebi V. Genetic similarities and differences between lobular in situ neoplasia (LN) and invasive lobular carcinoma of the breast. Virchows Arch 2006, 449(1):14-23. 10.1007/s00428-006-0192-7, 16612623.
34. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, Belinsky SA. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000, 60(21):5954-5958.
35. van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruine AP, Goldbohm RA, Brandt PA, Baylin SB, de Goeij AF, Herman JG. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 2003, 63(12):3133-3137.
36. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18(11):1427-1431. 10.1093/bioinformatics/18.11.1427, 12424112.
37. Latorra D, Campbell K, Wolter A, Hurley JM. Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers. Hum Mutat 2003, 22(1):79-85. 10.1002/humu.10228, 12815597.
38. Liikanen E. Common technical specification for in vitro diagnostic medical devices. Official Journal of European Community 2002, L131:17-30.
39. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, Otten P, VanMelle G, deTribolet N, Stupp R. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10(6):1871-1874. 10.1158/1078-0432.CCR-03-0384, 15041700.
40. Gorlia T, Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol 2008, 9(1):29-38. 10.1016/S1470-2045(07)70384-4, 18082451.
41. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003, 35(1):152-156.
42. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93(18):9821-9826. 10.1073/pnas.93.18.9821, 38513, 8790415.
43. Thomassin H, Kress C, Grange T. MethylQuant: a sensitive method for quantifying methylation of specific cytosines within the genome. Nucleic Acids Res 2004, 32(21):e168. 10.1093/nar/gnh166, 535695, 15576675.
44. Hattermann K, Mehdorn HM, Mentlein R, Schultka S, Held-Feindt J. A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis. Anal Biochem 2008, 377(1):62-71. 10.1016/j.ab.2008.03.014, 18384736.
45. Roversi G, Pfundt R, Moroni RF, Magnani I, van Reijmersdal S, Pollo B, Straatman H, Larizza L, Schoenmakers EF. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines. Oncogene 2006, 25(10):1571-1583. 10.1038/sj.onc.1209177, 16247447.
46. Yin D, Ogawa S, Kawamata N, Tunici P, Finocchiaro G, Eoli M, Ruckert C, Huynh T, Liu G, Kato M, et al. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res 2009, 7(5):665-677. 10.1158/1541-7786.MCR-08-0270, 19435819.
47. von Deimling A, Louis DN, von Ammon K, Petersen I, Hoell TCRY, Martuza RL, Schoenfeld DA, Yaşargil MG, Wiestler OD. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J Neurosurg 1992, 77:295-301. 10.3171/jns.1992.77.2.0295, 1320666.
48. Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, Aldape KD, Bogler O, Yung WK, Coombes K, et al. Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One 2008, 3(12):e4076. 10.1371/journal.pone.0004076, 2605252, 19115005.
49. Gardina PJ, Lo KC, Lee W, Cowell JK, Turpaz Y. Ploidy status and copy number aberrations in primary glioblastomas defined by integrated analysis of allelic ratios, signal ratios and loss of heterozygosity using 500K SNP Mapping Arrays. BMC Genomics 2008, 9:489. 10.1186/1471-2164-9-489, 2576260, 18928532.
50. Lo KC, Bailey D, Burkhardt T, Gardina P, Turpaz Y, Cowell JK. Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2008, 47(3):221-237. 10.1002/gcc.20524, 18050302.
51. Hodgson JG, Yeh RF, Ray A, Wang NJ, Smirnov I, Yu M, Hariono S, Silber J, Feiler HS, Gray JW, et al. Comparative analyses of gene copy number and mRNA expression in GBM tumors and GBM xenografts. Neuro Oncol 2009, 11(5):477-87. 10.1215/15228517-2008-113, 19139420.
52. Bottema CD, Sommer SS. PCR amplification of specific alleles: rapid detection of known mutations and polymorphisms. Mutat Res 1993, 288(1):93-102.
53. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res 1989, 17(7):2503-2516. 10.1093/nar/17.7.2503, 317639, 2785681.
54. Maertens O, Legius E, Speleman F, Messiaen L, Vandesompele J. Real-time quantitative allele discrimination assay using 3' locked nucleic acid primers for detection of low-percentage mosaic mutations. Anal Biochem 2006, 359(1):144-146. 10.1016/j.ab.2006.07.039, 16962063.
55. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, et al. Novel poly(ADP-ribose) polymerase-1 inhibitor, AG1 restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 4361, 10(3):881-889.
56. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res 2005, 65(14):6394-6400. 10.1158/0008-5472.CAN-05-0715, 16024643.